RedHill Biopharma (RDHL) Retained Earnings (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Retained Earnings for 3 consecutive years, with -$414.8 million as the latest value for Q4 2024.
- Quarterly Retained Earnings fell 1.73% to -$414.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$414.8 million through Dec 2024, down 1.73% year-over-year, with the annual reading at -$414.8 million for FY2024, 1.73% down from the prior year.
- Retained Earnings for Q4 2024 was -$414.8 million at RedHill Biopharma, down from -$407.7 million in the prior quarter.
- The five-year high for Retained Earnings was -$407.7 million in Q4 2023, with the low at -$433.9 million in Q4 2022.
- Average Retained Earnings over 3 years is -$418.8 million, with a median of -$414.8 million recorded in 2024.
- The sharpest move saw Retained Earnings rose 6.02% in 2023, then fell 1.73% in 2024.
- Over 3 years, Retained Earnings stood at -$433.9 million in 2022, then rose by 6.02% to -$407.7 million in 2023, then decreased by 1.73% to -$414.8 million in 2024.
- According to Business Quant data, Retained Earnings over the past three periods came in at -$414.8 million, -$407.7 million, and -$433.9 million for Q4 2024, Q4 2023, and Q4 2022 respectively.